The clinical effect of felodipine and nifedipine in Raynaud's phenomenon.
Sixteen patients participated in a double-blind cross-over trial comparing the effect of two dosages of the new calcium entry blocker, felodipine, with nifedipine in the treatment of Raynaud's phenomenon. The effect was evaluated using a symptom recording system. As no difference was found between the 3 treatments, the lower dose of felodipine (10 mg) may be preferable as only one dose per day is necessary.